CompanyURGNNasdaqRa'Anana, L3

UroGen Pharma Ltd.

UroGen develops RTGel, a sustained-release hydrogel platform for urothelial cancers.

SEC EDGAR ClinicalTrials.gov investors.urogen.com

8-KAug 20Latest SEC filing, period to Aug 18

Aug 5Latest story

August 2026

UroGen posts $50.4 million ZUSDURI revenue, cites patent allowance and pipeline progress

Aug 5Quarterly updatemitomycin UGN-104

July 2026

UroGen registers Phase 1 dose-escalation trial of UGN-501 in recurrent NMIBC

Jul 24Trial updateUGN-501 UroGen Pharma Ltd.